全球降血糖药物消费的趋势:从药品销售数据 (2010-2021) 获得的洞察力
Myo Myo Swe Oo1, Sahan Jayawardana1, Allen Campbell2
1Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
PLOS global public health
|October 22, 2025
概括
从2010年到2021年,全球降血糖药物的消费量有所增加,高收入国家与低收入国家之间的差异很大. 这凸显了全球糖尿病治疗的未满足需求和获取差距.
科学领域:
- 药物经济学 药物经济学
- 全球健康 全球健康
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病是一种重大的全球健康挑战.
- 了解降血糖药物消费模式对于识别获取差异和未满足需求至关重要.
研究的目的:
- 分析从2010年到2021年消费降血糖药物的全球趋势.
- 为了比较不同收入层和不同国家的消费率.
- 调查基本药物,胰岛素和新型药物类别的消费情况.
主要方法:
- 使用IQVIA MIDAS数据进行消费分析.
- 雇员定义每天每千居民的每日剂量 (DDD/TID) 是消费指标.
- 分析了72个国家和2个地区2010-2021年间的数据,按收入水平分层.
主要成果:
- 在2010年至2021年期间,全球消费量从39.2 DDD/TID上升到54.0 DDD/TID.
- 高收入国家 (HICs) 持续显示出最高的消费率 (中位数为60.1 DDD/TID),而低收入和中低收入国家 (LMICs) 的消费率最低 (中位数为10.8 DDD/TID).
- 大多数药物类别的消费,包括胰岛素和新药,增加了,HICs领先于新药的吸收,UMICs/LMICs显示中间作用胰岛素使用的显著增长.
结论:
- 全球消费低血糖药物存在显著差异,特别是在HIC和LMIC之间.
- 这些发现强调了糖尿病管理的关键获取差距,特别是在中高收入和低收入国家.
- 需要进一步的研究和有针对性的干预措施,以改善全球平等获得必要的糖尿病药物.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
582
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
582
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
522
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
522
Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
Oral Hypoglycemic Agents: Glinides
595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K


